Ditemukan 10 dokumen yang sesuai dengan query :: Simpan CSV
ABSTRAK Nama : Vina Giolisa Permata Sari Program Studi : Pascasarjana Gizi Kesehatan Masyarakat Judul : Analisis Faktor yang Mempengaruhi Penurunan Berat Badan Ibu Postpartum di Kota Depok Tahun 2015 (Analisis Data Sekunder) Proses kehamilan akan menaikan berat badan ibu sekitar 6,8 - 18,40 kg. Setelah melahirkan, berat badan ibu hanya akan berkurang sekitar 5 - 6 kg. Penumpukan berat badan setelah melahirkan dapat membuat wanita menjadi overweight atau obesitas. Berdasarkan kondisi tersebut, banyak ibu postpartum yang melakukan diet pada masa menyusui agar kembali ke berat badan semula, sehingga asupan kalorinya kurang dari kebutuhan. Padahal kebutuhan ibu menyusui (2530 - 2600 kkal/hari) lebih banyak dibandingkan saat hamil (2380 - 2500 kkal/hari). Hal ini menyebabkan ibu gagal memberikan ASI eksklusif yang sebenarnya dapat membantu penurunan berat badan pasca melahirkan. Penelitian ini menggunakan data sekunder dari penelitian Fikawati (2015) yang menggunakan desain penelitian kohort prospective pada ibu menyusui di Kota Depok. Tujuan penelitian ini adalah untuk mengetahui faktor-faktor yang mempengaruhi penurunan berat badan ibu postpartum. Sampel penelitian berjumlah 201 ibu menyusui yang dipantau hingga 6 bulan postpartum. Variabel yang diteliti terdiri dari usia, pendidikan, paritas, status bekerja, pemberian ASI eksklusif dan asupan energi selama menyusui. Hasil penelitian menunjukkan sebanyak 89% ibu mengalami penurunan berat badan pasca 6 bulan postpartum sedangkan sisanya sebanyak 11% justru mengalami kenaikan berat badan. Terdapat hubungan yang signifikan antara tingkat pendidikan (p=0,041) dan pemberian ASI eksklusif (p=0,004) dengan penurunan berat badan postpartum. Faktor yang paling dominan mempengaruhi penurunan berat badan adalah ASI eksklusif. Setiap ibu yang memberikan ASI eksklusif pada bayinya, berat badannya akan berkurang sebanyak 1,792 kg setiap bulannya. Disarankan agar ibu tidak melakukan diet berlebih dan tetap memberikan ASI eksklusif 6 bulan kepada bayinya Kata Kunci : ASI eksklusif, Penurunan berat badan, Postpartum, Retensi Berat Badan
ABSTRACT Name : Vina Giolisa Permata Sari Major : Graduate Program Public Health Nutrition Title : Analysis of Factors Affecting Postpartum Weight Loss in Depok City 2015 (Secondary Data Analysis) Pregnancy will increase mother’s weight about 6.8 - 18.40 kg. After delivery, the weight decrease only about 5 - 6 kg. The retention of postpartum weight will made mother being overweight or obese. Based on these conditions, many postpartum mothers do diet during breastfeeding to return the weight as before pregnant, so that their calorie intake less than they needs. Though the needs of breastfeeding mothers (2530 - 2600 kcal / day) more than pregnant (2380 - 2500 kcal / day). This condition causes mother failed to give an exclusive breastfeeding that can actually help postpartum weight loss. This study used secondary data from Fikawati’s study (2015) with prospective cohort study designs in breastfeeding mothers in Depok City. The purpose of this study was to determine the factors that influence postpartum weight loss. The sample of the study was 201 breastfeeding mothers which monitored for up to 6 months postpartum. The variables studied consisted of age, education, parity, working status, exclusive breastfeeding and energy intake during breastfeeding. The results showed about 89% of mothers lose weight after 6 months postpartum while the remaining 11% actually gained weight. There was a significant correlation between education level (p = 0,041) and exclusive breastfeeding (p = 0,004) with postpartum weight loss. The most dominant factor influencing weight loss is exclusive breastfeeding. Every mother who exclusively breastfed her baby will lose weight as much as 1,792 kg monthly. It is recommended that mothers does not need to do extremely diet and give an exclusive breastfeeding for 6 months Keywords : Exclusive Breastfeeding, Postpartum, Retention, Weight Loss
Literature describing energy intake of lactating mothers in Indonesia is still lowand does not meet the nutritional needs based on the Recommended DietaryAllowances. The first objective of this study was to determine energycomsumption of pregnant women as a dominant factor on energy consumption oflactating women in beji district, depok 2016. The study included 146 lactatingmother in Beji District. The results showed association between maternalcharacteristics (age, parity and breastfeeding knowledge), energy consumptionduring pregnancy, postpartum nutritional status, and socio-economics status(education, maternal work status, and family meal expenses) towards maternalenergy consumption during lactation, as energy consumption during pregnancy isthe dominant factor.Keywords: energy consumption, lactating women.
ABSTRAK Nama : Wirda Syari Program Studi : Magister Ilmu Kesehatan Masyarakat Judul : Evaluasi Ekonomi Parsial Antara Pemberian Terapi Rivaroxaban dan Terapi Kombinasi (UFH + Warfarin) untuk Pengobatan Trombosis Vena Dalam (Deep Vein Thrombosis) pada Pasien Kanker di Rumah Sakit Kanker Dharmais Tahun 2016 – 2018 Pembimbing : Dr. drg. Mardiati Nadjib, MS Berdasarkan penelitian-penelitian sebelumnya, diketahui bahwa terapi rivaroxaban memiliki beberapa kelebihan dibandingkan dengan terapi kombinasi (UFH + warfarin) untuk pengobatan trombosis vena dalam (deep vein thrombosis/DVT). Akan tetapi, masih sedikit dokter di RS Kanker Dharmais yang memberikan terapi rivaroxaban untuk pengobatan DVT. Penelitian evaluasi ekonomi parsial ini bertujuan untuk menganalisis efektivitas/outcome dan besarnya biaya yang dibutuhkan dari perspektif rumah sakit antara pemberian terapi rivaroxaban dan terapi kombinasi (UFH + warfarin) untuk pengobatan DVT pada pasien kanker di Rumah Sakit Kanker Dharmais tahun 2016 – 2018. Karena keterbatasan jumlah pasien yang mendapatkan terapi rivaroxaban selama 3 – 6 bulan, studi ini menganalisis biaya dan efektivitas/outcome dari pasien yang mendapatkan terapi selama 1 bulan. Efektivitas/outcome yang diukur adalah intermediate outcome, yang meliputi lama hari rawat, kesembuhan, dan kejadian perdarahan. Biaya dihitung berdasarkan biaya yang dibebankan kepada pasien (charge), yang meliputi biaya obat, pemeriksaan penunjang, tindakan, serta administrasi dan akomodasi. Hasil penelitian menunjukan bahwa untuk efektivitas/outcome terapi rivaroxaban, sebagian besar pasien tidak mendapatkan perawatan rawat inap, 40% pasien dinyatakan sembuh dari DVT, dan tidak ada pasien yang mengalami kejadian perdarahan. Rata-rata biaya terapi rivaroxaban hingga mencapai outcome yang diharapkan adalah Rp 8.824.791,00. Untuk efektivitas/outcome terapi kombinasi (UFH + warfarin), sebagian besar pasien memiliki lama hari rawat antara 8 – 14 hari, 46% pasien dinyatakan sembuh dari DVT, dan tidak ada pasien yang mengalami kejadian perdarahan. Rata-rata biaya terapi kombinasi (UFH + warfarin) hingga mencapai outcome yang diharapkan adalah Rp 13.201.698,00. Kata Kunci: Evaluasi ekonomi; kanker; rivaroxaban; trombosis vena dalam; warfarin
ABSTRACT Name : Wirda Syari Study Program : Magister of Public Health Title : Partial Economic Evaluation Between Rivaroxaban Therapy and Combination Therapy (UFH + Warfarin) for the Treatment of Deep Vein Thrombosis in Cancer Patients at Dharmais Cancer Hospital during 2016 - 2018 Counsellor : Dr. drg. Mardiati Nadjib, MS Based on previous studies, rivaroxaban therapy has several advantages compared to combination therapy (UFH + warfarin) for the treatment of deep vein thrombosis (DVT). However, the use of rivaroxaban in Dharmais Cancer Hospital is still low. This partial economic evaluation study aims to analyze cost and consequence of rivaroxaban therapy and combination therapy (UFH + warfarin) for DVT treatment in cancer patients at the Dharmais Cancer Hospital during 2016 – 2018. Data collection was done using cohort-retrospective and individual unit of analysis. Due to limited number of patient treated with rivaroxaban therapy within 3-6 months, we estimated the cost and consequence related to patients who were successfully treated in one month. The consequence was the intermediate outcome, i.e length of stay, recovery, and the occurrence of bleeding. The cost was calculated based on hospital perspective including drugs, laboratory tests, procedures, as well as the administrative and accommodation costs. The results showed that patients with rivaroxaban therapy were not admitted to inpatient care, 40% of patients were recovered from DVT, and none of the patients experienced bleeding. The average cost of rivaroxaban therapy to reach the expected outcome was Rp 8,824,791.00. The study also showed that the outcome of combination therapy (UFH + warfarin) were length of stay between 8 to 14 days, 46% of patients were recovered from DVT, and none of the patients experienced bleeding. The average cost of combination therapy (UFH + warfarin) to reach the expected outcome was Rp 13,201,698.00. Key words: Cancer; deep vein thrombosis; economic evaluation; rivaroxaban; warfarin
